DK0416232T3 - Stabil injicerbar farmaceutisk formulering med folsyre- og leukovorinsalte og fremgangsmåde - Google Patents

Stabil injicerbar farmaceutisk formulering med folsyre- og leukovorinsalte og fremgangsmåde

Info

Publication number
DK0416232T3
DK0416232T3 DK90112426.3T DK90112426T DK0416232T3 DK 0416232 T3 DK0416232 T3 DK 0416232T3 DK 90112426 T DK90112426 T DK 90112426T DK 0416232 T3 DK0416232 T3 DK 0416232T3
Authority
DK
Denmark
Prior art keywords
salts
folic acid
leukovoric
pharmaceutical formulation
injectable pharmaceutical
Prior art date
Application number
DK90112426.3T
Other languages
English (en)
Inventor
Bruce Edwin Haeger
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0416232T3 publication Critical patent/DK0416232T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK90112426.3T 1989-08-21 1990-06-29 Stabil injicerbar farmaceutisk formulering med folsyre- og leukovorinsalte og fremgangsmåde DK0416232T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39657389A 1989-08-21 1989-08-21

Publications (1)

Publication Number Publication Date
DK0416232T3 true DK0416232T3 (da) 1995-09-18

Family

ID=23567787

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90112426.3T DK0416232T3 (da) 1989-08-21 1990-06-29 Stabil injicerbar farmaceutisk formulering med folsyre- og leukovorinsalte og fremgangsmåde

Country Status (11)

Country Link
EP (1) EP0416232B1 (da)
JP (1) JP3043381B2 (da)
KR (1) KR0159768B1 (da)
AT (1) ATE126438T1 (da)
AU (1) AU628211B2 (da)
CA (1) CA2023563C (da)
DE (1) DE69021673T2 (da)
DK (1) DK0416232T3 (da)
ES (1) ES2076263T3 (da)
GR (1) GR3017143T3 (da)
PT (1) PT95026B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
CH687062A5 (de) * 1994-02-14 1996-09-13 Cerbios Pharma Sa Konzentrierte Injektionsloesung von Alkalimetallsalzen von reduzierten Folaten.
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
JP4545632B2 (ja) * 2005-04-25 2010-09-15 株式会社 伊藤園 葉酸含有組成物及び葉酸の安定化方法
JP4919024B2 (ja) * 2006-11-16 2012-04-18 横河電機株式会社 圧力センサ
JP4906546B2 (ja) * 2007-03-15 2012-03-28 株式会社ヤクルト本社 レボホリナート含有水溶液製剤
WO2014112392A1 (ja) 2013-01-21 2014-07-24 パナソニック株式会社 赤外線検出素子、赤外線検出器及び赤外線式ガスセンサ
JP6057254B2 (ja) * 2013-01-23 2017-01-11 パナソニックＩｐマネジメント株式会社 赤外線受光ユニット、赤外線式ガスセンサ
EP2799060A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition comprising levoleucovorin
EP2799061A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
WO2016123076A1 (en) * 2015-01-27 2016-08-04 La Vita Compounding Pharmacy Stable 5-methyltrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
CN117224478B (zh) * 2023-10-21 2026-02-06 陕西丽彩药业有限公司 一种盐酸乌拉地尔注射液及其制备方法
CN118059042A (zh) * 2024-04-17 2024-05-24 成都瑞尔医药科技有限公司 一种亚叶酸钙注射液及其制备方法
US12564592B1 (en) 2024-12-23 2026-03-03 Riconpharma LLC Injectable leucovorin formulations and methods of preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695860A (en) * 1952-04-29 1954-11-30 American Cyanamid Co Stabilized pteroyl solutions
US4071620A (en) * 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
WO1988004927A1 (en) * 1986-12-31 1988-07-14 Davirand, Inc. Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid

Also Published As

Publication number Publication date
EP0416232A3 (en) 1992-01-02
CA2023563C (en) 2000-02-22
PT95026B (pt) 1997-12-31
DE69021673D1 (de) 1995-09-21
GR3017143T3 (en) 1995-11-30
JPH0390026A (ja) 1991-04-16
KR910004194A (ko) 1991-03-28
ES2076263T3 (es) 1995-11-01
EP0416232A2 (en) 1991-03-13
PT95026A (pt) 1991-04-18
AU628211B2 (en) 1992-09-10
KR0159768B1 (ko) 1998-12-01
JP3043381B2 (ja) 2000-05-22
EP0416232B1 (en) 1995-08-16
DE69021673T2 (de) 1996-05-02
CA2023563A1 (en) 1991-02-22
AU6116590A (en) 1991-02-21
ATE126438T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
DK0416232T3 (da) Stabil injicerbar farmaceutisk formulering med folsyre- og leukovorinsalte og fremgangsmåde
IT1200589B (it) Derivati naturali attivita farmagologica
ATE245033T1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
PT84663B (pt) Processo para a preparacao de novas composicoes farmaceuticas de accao prolongada contendo compostos activos praticamente insoluveis, especialmente dihidropiridinas substituidas
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
ES2073222T3 (es) Sales estables de acido 5,10-metilen-tetrahidrofolico.
NO902488D0 (no) Karboplatinapreparat.
ATE65401T1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
ATE97572T1 (de) Azelastin enthaltende arzneimittel mit kontrollierter wirkstoffabgabe.
AR245591A1 (es) Una composicion oral estable, con propiedades antiplaca y antigingivales mejoradas.
ATE117313T1 (de) Stabile lösungen von rebeccamycinderivaten sowie deren herstellung.
DK52685A (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og mellemprodukter ved deres fremstilling samt farmaceutisk praeparat
ES8203221A1 (es) Procedimiento para preparar una composicion antihelmintica acuosa termicamente reversible
IL76393A (en) Stable parenteral aqueous pharmaceutical compositions of dezocine
TH2950B (th) สารแขวนลอยซูครัลเฟท